Introduction
weight loss, time to progression, number and type of metastases [13] , vascular invasion [14] and several Prognostic markers include factors measurable in serum or tissue specimens using an assay; quantitative or laboratory values, e.g. haemoglobin level, ESR and alkaline phosphatase levels, have been studied in relation to qualitative changes from a defined baseline level are correlated with prognosis. Ideally, a prognostic marker prognosis [13] . Increasing knowledge of cytogenetic abnormalities and the role of oncogenes and tumour should have high specificity, sensitivity and reproducibility. It should be organ-and cancer-specific, and have suppressor genes in RCC is critical, but the study of molecular mechanisms underlying RCC is still in its the power to predict the prognosis. Furthermore, its assessment should be practical, easy and cost-eCective.
infancy; future studies will have to provide information on the implications for the prognosis of patients with A prognostic marker should be useful in patient management and clinical-decision making, resulting in improved RCC. clinical outcome.
However, the ideal prognostic marker has not been Stage discovered for any of the urological malignancies. Few markers are routinely used in clinical decision-making
The TNM system, which explicitly defines the anatomical extent of disease, is the most commonly used staging or have been studied in clinical trials. In this review, we discuss the clinical use of tissue-related prognostic factors system. Several studies have shown that stage is the most consistent single prognostic factor to influence in RCC and bladder cancer, and review the published literature on experimental prognostic markers.
survival [5] [6] [7] [8] 15] . Survival is inversely correlated with pathological stage as patients with tumours confined to the kidney have significantly better disease-specific surRenal cell cancer vival rates than patients with metastatic RCC [16] . The significance of invasion into the renal vein, vena cava, Radical surgical extirpation of a kidney tumour remains the only eCective means of curing localized RCC, despite renal pelvis, perinephric fat and lymph nodes has been the subject of much debate [12] . Most studies do not alternative forms of therapy which have been proposed over the last decade. Patients with metastatic RCC have regard renal vein invasion as a factor that reduces survival [6, 9, 17] . Tumour penetration into the renal a poor prognosis, with a median survival of approximately 8 months [1] and limited therapeutic options; pelvis was thought to reflect tumour stage rather than biological behaviour and is therefore not an independent RCC is resistant to most conventional cytotoxic agents [2] . More recently, the use of biological response modiprognosticator [16] . Data addressing the issue of inferior vena cava invasion are conflicting. Several large series fiers, especially IL-2 and IFNa, has lead to some responses in patients with metastatic disease [3, 4] .
found that invasion of the vena cava minimally aCected survival, as long as the tumour thrombus could be The clinical course of metastatic RCC is variable. To obtain an insight into the clinical and biological behavtotally removed [18, 19] . Patients with RCC invading the renal capsule and perinephric fat have a worse survival iour of RCC the identification of new prognostic factors is vital. Eventually, the use of these factors should than those with organ-confined disease [20, 21] . Lymph node invasion is an ominous prognostic sign and has a facilitate the choice of optimal treatment for individual patients. Investigators have attempted to identify pathosignificant impact on survival [9, 22] . From these retrospective studies it is uncertain if patients with positive logical and morphological features within the tumour that correlate with survival in patients with RCC.
lymph nodes would benefit from lymph node dissection. Whether extended lymphadenectomy improves the surTumour stage remains the most important factor predictive of survival in RCC [5] [6] [7] [8] . In addition, tumour size vival of patients with RCC may be answered by the ongoing EORTC 30881 randomized trial. Patients with [7] , histological pattern [9], cell type [9], nuclear grade [7] , DNA content [10] and nuclear morphometry [11] metastatic RCC have a poor prognosis, with 5-and 10-year survival rates of 5-10% and 0-7%, respectively. have been reported as prognosticators for survival.
Despite great eCort to challenge metastatic disease with tumours being associated with a less favourable outcome. However, most studies did not account for tumour stage, adjuvant treatments, the overall survival of patients has not been improved. Survival probably depends on the histological grade or tumour heterogeneity, and there were too few patients in these studies to draw definite biological aggressiveness of the tumour and not on the site(s) of metastatic lesions, although pulmonary metastconclusions about this potential prognosticator. ases appear to be associated with a better prognosis. In selected cases, excision of solitary lesions may improve Cytogenetic findings the duration of overall survival [23] . In retrospective analyses, nephrectomy in patients with systemic disease Cytogenetic analysis has shown a close correlation between certain recurrent chromosomal rearrangements did not alter the subsequent disease course [17] . Only a select group of patients who were relatively more suitable and several RCC subtypes [32] . Clear cell carcinomas have deletions or translocations involving the short arm to undergo surgery and had a few surgically resectable metastases may have benefited from nephrectomy with of chromosome 3, with breakpoints proximal to 3p22. Papillary tumours have allelic losses of 17p or trisomies extirpation of metastatic lesions. With the development of modern immunotherapy, this issue needs to be of chromosomes 7, 16 and/or 17. Chromophobic cell carcinomas have hypodiploid chromosome numbers, re-addressed. In an EORTC study (protocol 30947) patients with metastatic RCC are randomized to either oncocytomas have deletions (−Y and −1) and collecting duct carcinomas have been characterized by deletions immunotherapy alone or tumour nephrectomy followed by immunotherapy. This important study should shed −1, −6, −14, −15 and −22. Some tumours with predominantly papillary/chromophilic histology and further light on the role of nephrectomy in metastatic RCC and may well change current attitudes towards translocations in Xp11.2 have been reported [33] . It has been suggested that RCC may be subdivided into diCerent how we treat this condition.
groups based on genetic abnormalities and that these cytogenetic aberrations may be of prognostic importance Grade [33, 34] . Other authors found no correlation between cytogenetic changes and prognosis [35] [36] [37] . In a recent The grading of RCC has proved to be diBcult; Skinner et al. [6] and Fuhrman et al.
[24] developed grading study, Elfving et al. [32] evaluated the prognostic impact of cytogenetic findings in RCC in 50 patients. Patients systems based on nuclear morphometry of RCC cells. Several studies reported the independent prognostic with more than five cytogenetic findings had a significantly worse prognosis than patients with fewer changes. value of grade in predicting long-term survival [6, 17, 24, 25] . Tumour cell type (i.e. clear granular,
Patients with deletions (8p)/−8,+12 and +20 had a significantly worse prognosis. However, grade was the spindle or mixed) also appears to influence survival. Tumours with spindle cells are significantly more maligmost reliable independent prognosticator for recurrent disease in this study. Further studies, involving more nant than the other cell types [6, 26] . Although nuclear grade is an independent prognosticator, it is usually only patients, are needed to evaluate the implications of karyotypic changes in RCC. second to stage in significance, as lack of uniformity and inherent subjectivity of grading systems have prevented their widespread application.
Vascular invasion
In a recent study, the correlation between microscopic Nuclear morphometry vascular tumour invasion and disease-free interval after surgery for RCC was examined [14] . Compared with Morphometric analysis of renal carcinoma cells appears to predict survival, as shown in several studies [27] [28] [29] .
classical tumour stage, grade and tumour diameter, microvascular invasion was found to be the single most In one study, the 5-year survival rates were significantly poorer if the nuclear area was >35 mm2 [27] . Further relevant prognosticator after presumed curative radical nephrectomy for RCC. In patients undergoing radical studies are necessary with larger groups of patients to confirm the value of nuclear morphometry as a prognosnephrectomy for clinically nonmetastatic RCC with microvascular invasion but without lymph node involvetic factor. ment or macroscopic vascular invasion, the chance of disease progression was estimated at 45% within one DNA content year. Several groups have reported that tumour DNA content as measured by flow cytometry may have prognostic value in patients with RCC [10, 30, 31] , with aneuploid detection methods are being developed in an attempt to Clinical and laboratory variables identify and monitor those patients with noninvasive bladder cancer who are at risk of developing recurrent The overall survival rate among young adults with RCC is similar to that of older patients [38] and hence age or progressive disease. Patients with muscle-invasive disease may benefit from the use of markers that predict does not appear to have prognostic significance. The adverse impact of male gender in RCC has been suggested a tumour's metastatic potential and the outcome of therapy. We will discuss the available prognostic mark- [38] but several large studies, using multivariate analysis, did not confirm male sex as a prognostic factor ers, of which relatively few have confirmed clinical utility. Nevertheless, in the near future, the increased [17, 39] . Most diCerences in survival between the sexes are related to diCerences in stage and grade of tumours.
use of new prognostic factors may modify the way we manage patients with TCC of the bladder. Several authors have reported the prognostic importance of diCerent signs and symptoms. Weight loss [17, 26, 38, 40, 41] and performance status [13, 40] are Stage important, but are also associated with advanced stages.
Various laboratory results may be adversely related to The selection of initial therapy currently depends on clinicopathological variables. Tumour stage, reflecting prognosis. Using univariate analysis, Citterio et al. [13] reported that anaemia at diagnosis predicted a poor depth of invasion, remains the most common prognosticator for progression. Several studies have shown that outcome of metastatic RCC, as well as hypercalcaemia, hypoalbuminaemia and high serum alkaline phosphathe risk for progression is significantly greater in T1 than Ta tumours [44] . tase. The ESR has also been related to a poor prognosis [42] . Serum levels of erythropoietin correlate with tumour stage and grade, and may provide prognostic Grade information [43] .
The grading system involves three classes and is based on the degree of anaplasia. Several studies have shown Bladder cancer cytometric studies [46, 47] . However, it is questionable whether ploidy provides additional information to TCC of the bladder can be classified into two groups with distinct behaviour and prognosis; low-grade tumours tumour grade and stage [11, 48] . Cellular DNA content may be of prognostic value only in grade 2 TCC, as most (papillary and usually noninvasive) and high-grade tumours (papillary or nonpapillary and often invasive). grade 1 tumours are diploid and most grade 3 tumours are aneuploid [49] . TCC of the bladder consists of noninvasive tumours (Ta, Tis and T1) for 75-85% of patients and invasive (T2, Stöckle et al.
[50] using paraBn-embedded bladder carcinoma tissue from radical cystectomy, found that in T3, T4) or metastatic tumours in 15-25%. Of the patients with noninvasive bladder cancer, >70% will case of noninvasive tumours, DNA cytometry identified potentially invasive tumours. Monosomy of chromohave one or more recurrences after initial treatment and in a third progressive disease will develop. Primary somes 13 and 22 was correlated with a poor prognosis and trisomy of chromosomes 7 with a favourable progtherapy is based on clinical staging and morphological assessment. However, tumours may behave diCerently nosis [51] . However, bladder cancers consist of cell populations heterogeneous in ploidy. A 'non-tetraploid' despite morphological similarity. It is of great importance to identify patients with noninvasive tumours who are DNA aneuploidy in a bladder washing specimen is considered to be recurrent tumour in patients with likely to develop recurrent or progressive disease; tumour markers may contribute to this goal. Recent developnoninvasive bladder cancer treated by TUR. DNA aneuploidy Á 6 months after intravesical treatment of nonments in molecular and genetic techniques have contributed to our understanding of bladder cancer tumour invasive tumours is a good prognosticator for treatment failure and progression [49] . The prognostic value of biology. Biological markers and new bladder cancer DNA ploidy in muscle-invasive TCC remains debatable.
had a significantly higher recurrence rate and lower survival rate than cases with moderate Rb expression The routine use of flow cytometry and image analysis of morphonuclear variables requires further clinical studies [61] . In the same study, patients with tumours showing both altered p53 and Rb expression had significantly and standardization of techniques.
increased rates of recurrence and decreased survival. The authors concluded that bladder tumours highly P53 tumour suppressor gene expressing Rb showed no tumour-suppressor eCects of the protein and that alterations in both p53 and Rb may The tumour suppressor gene p53 is located on chromosome 17p13-1 and codes for a 53-kDa nuclear phosphoact together or synergistically to promote tumour progression. protein. The role of p53 is critical to cell cycle control, resulting in cell cycle arrest to allow DNA repair or induction of apoptosis in the event of irreparable DNA E-cadherin damage. Inactivation of p53 by deletion and/or mutation results in loss of tumour suppressive function. Bladder
Decreased expression of E-cadherin may play a role in tumour invasion and metastasis, as E-cadherin-mediated cancer, especially of the invasive type, is associated with a high frequency of p53 mutations. Several immunocell-cell adhesion appears to play a critical role in epithelial integrity [62] . Loss of E-cadherin expression histochemical studies have confirmed that altered expression of the protein product(s) of mutated p53 is may be an important prognostic factor. Decreased E-cadherin immunoreactivity was shown to correlate associated with tumour progression in patients with T1 bladder cancer [52, 53] . Patients with p53-positive with both increased grade, stage and poor prognosis in patients with bladder tumours [63] [64] [65] . Another study nuclear staining had a significantly shorter disease-free interval. The frequency of p53 mutations may thus reported an inverse relation between recurrence-free survival and E-cadherin expression in bladder cancer predict clinical aggressiveness. In contrast, a further study, this time of invasive tumours, applying PCR-SSCP biopsies [66] . Using multivariate analysis, E-cadherin expression had no independent prognostic significance to assess the mutational status of p53, found no significant association with survival [54] . This may reflect the over grade and stage. Otto et al. [67] showed that downregulation of E-cadherin in association with an increase discrepancy between p53 mutation analysis and p53 immunohistochemistry. In another study of patients with in gp78, an autocrine motility factor receptor, was associated with a poor prognosis. The combined appli-TCC confined to the bladder, an accumulation of p53 in the tumour-cell nuclei predicted a significantly increased cation of these two antigens may identify patients with high-risk bladder cancer and influence treatment risk of recurrence and death, independently of tumour grade, stage and lymph-node status [55] . In two recent decisions. studies, p53 nuclear reactivity did not indicate the outcome of chemotherapy for metastatic disease [56, 57] .
Epidermal growth factor receptor (EGFR) Large prospective studies are needed to evaluate the nuclear overexpression of p53 protein as a prognostic An immunohistochemical study in patients with noninvasive TCC (pTa, pT1) showed that overexpression of marker in bladder cancer.
EGFR, the product of the c-erbB-1 gene, was correlated with a significantly higher recurrence rate, shorter time Retinoblastoma gene to recurrence and higher tumour progression [68] . EGFR-positive patients with muscle-invasive disease Loss of heterozygosity at chromosome 13q14, the site of the retinoblastoma (Rb) gene, occurs in bladder cancer showed no diCerence in survival.
Overexpression of the c-erbB-2 gene product, a transwith a wide range of incidence [58] . Rb is a tumoursuppressor gene whose protein product has a function membrane growth factor receptor with significant sequence homology to EGFR, correlated with tumour in cell-cycle control. Loss of Rb function may result in increased genetic instability and can occur in both grade and survival [69] . Its expression was an independent prognosticator in a multivariate analysis. However, noninvasive and invasive bladder tumours, most commonly in the latter. Several immunohistochemical studconflicting results have been published in a study reporting no additional prognostic power over tumour ies have shown that decreased expression of Rb protein is associated with more aggressive biological behaviour grade, DNA aneuploidy and proliferative activity (reviewed in [70] ). EGFR overexpression can be used as and a decreased life expectancy [59, 60] . A recent study, evaluating the expression of Rb in bladder tumours from a prognosticator in noninvasive bladder cancer. The prognostic value of the c-erbB-2 oncoprotein needs patients who had undergone cystectomy, reported that both cases with undetectable Rb and high Rb expression further evaluation. 
